Sarepta Pauses Elevidys Shipments Amid Safety Concerns
TL;DR
Sarepta Therapeutics announced it will voluntarily halt all shipments of its gene therapy Elevidys in the U.S. to address FDA concerns following patient deaths and label updates, leading to a significant stock decline and raising questions about its future prospects and regulatory relationships.
- Sarepta Makes A 'Painful' Decision, And Shares Tumble Investor's Business Daily
- Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. Sarepta Therapeutics
- Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy The Boston Globe
- Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths The New York Times
- Sarepta to pause gene therapy Elevidys shipments in U.S. CNBC
Want the full story? Read the original reporting
Read on Investor's Business Daily